Aryl-quinoline derivatives

US9199938B2 · kind B2 · utility

Assignee

• Hoffmann-La Roche Inc. · US

Inventors

• Simona M. Ceccarelli · Basel, CH
• Aurelia Conte · Basel, CH
• Holger Kuehne · Soest, DE
• Bernd Kuhn · Sursee, CH
• Werner Neidhart · Hagenthal-le-Bas, FR
• Ulrike Obst Sander · Sursee, CH
• Markus Rudolph · Basel, CH

Key dates

• Filing date: Nov 1, 2012
• Grant date: Dec 1, 2015
• Expiry date: Mar 30, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/14
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The invention provides novel compounds having the general formula (I)wherein R1, R2, R3, R4, R5, R6 and n are as described herein, compositions including the compounds and methods of using the compounds. The present compounds are useful as fatty-acid binding protein (FABP) 4 and/or 5 inhibitors and may be used for the treatment or prophylaxis of lipodystrophy, type 2 diabetes, dyslipidemia, atherosclerosis, liver diseases involving inflammation, steatosis and/or fibrosis, such as non-alcoholic fatty liver disease, in particular non-alcoholic steatohepatitis, metabolic syndrome, obesity, chronic inflammatory and autoimmune inflammatory diseases.